Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

Table 1 baseline subject characteristics

Characteristics at inpatient screening	Exenatide n = 28	Placebo n = 26
Age, years^a	57 ± 11	54 ± 10
Gender, male, n (%)	19 (68)	11 (42)
Race, n (%)
Caucasian	24 (86)	25 (96)
African	2 (7)	0 (0)
East Asian	1 (4)	1 (4)
Hispanic	1 (4)	0 (0)
Weight, kg^a	91.6 ± 15.2	85.9 ± 12.2
BMI, kg/m^2a	29.5 ± 3.4	30.1 ± 3.9
Hemoglobin A_1c, %^a	7.5 ± 0.9	7.1 ± 0.7
Duration of diabetes^a	7 ± 4	6 ± 4
HR, beats/minute^a	75.2 ± 12.4	73.7 ± 9.0
SBP, mm Hg^a	139.4 ± 13.9	138.6 ± 18.7
DBP, mm Hg^a	83.1 ± 7.4	80.1 ± 12.2
Vital signs collected by ambulatory BP monitoring
HR, beats/minute^a
24-hour	74.4 ± 11.0	74.5 ± 9.7
Daytime	75.5 ± 12.0	75.4 ± 10.5
Nighttime	71.2 ± 10.5	71.8 ± 11.1
SBP, mm Hg^a
24-hour	126.4 ± 16.6	119.9 ± 14.0
Daytime	128.0 ± 19.4	121.2 ± 14.7
Nighttime	122.0 ± 14.5	116.1 ± 14.8
DBP, mm Hg^a
24-hour	75.2 ± 11.1	70.5 ± 9.9
Daytime	77.0 ± 12.4	72.1 ± 10.6
Nighttime	69.8 ± 11.6	65.8 ± 10.4

^aMean ± standard deviation; intent-to-treat population shown; BMI, body mass index; BP, blood pressure; DBP, diastolic BP; HR, heart rate; SBP, systolic BP

ISSN: 1475-2840